StockData
iBio, Inc. logo

iBio, Inc. (IBIO) income statement

IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$0.85+0.10 (+13.37%)

Close on Nov 18, 2026Market cap $54.54MP/E –Yield –

iBio, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-3491.0%
Net margin
-3244.2%
Return on equity, FY2026
-65.7%

Financial strength

Current ratio
9.48
Debt to equity
–
Debt to assets
–
Cash to current liabilities
529.9%

Valuation

P/E ratio
–
Price to sales
50.73
Price to book
0.69
Dividend yield
–

See a number that looks wrong?